Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210684 · ClinicalTrials.gov registry record · NA
Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes
A NA study of PreDiabetes, sponsored by Nanjing Nutrabuilding Bio-tech Co..
- Recruiting
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT07210684: Recruiting NA study of PreDiabetes, sponsored by Nanjing Nutrabuilding Bio-tech Co..
NCT07210684 is a NA study of PreDiabetes that is actively recruiting participants, run by Nanjing Nutrabuilding Bio-tech Co.. The registered enrollment target is 54 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07210684, a NA study of PreDiabetes, is actively recruiting participants, sponsored by Nanjing Nutrabuilding Bio-tech Co..
- RECRUITING
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if Dihydroberberine (DHB) supplementation affects adults with pre-diabetes. The main questions it aims to answer are: Does DHB supplementation increase the concentration of GLP-1 in the blood? Does DHB supplementation affect appetite, mood, and energy levels? Does DHB supplementation affect body weight, blood sugar control and insulin? Researchers will compare DHB supplementation to a placebo (a look-alike substance that contains no drug) to see if DHB has any effect. Participants will: Take DHB or a placebo every day for 6 weeks. Participate in tests to measure GLP-1 levels, blood glucose, insulin and other markers. Have their continuous blood sugar profiles (with CGMs) monitored to see how much time their blood sugar spends in a healthy range. Rate their appetite, mood, and energy levels using a visual analog scale.
Primary Outcome
Change in postprandial total glucagon-like peptide-1 (GLP-1) maximum concentration (Cmax) following a single dose of 200 mg DHB compared to placebo, measured at visit 3, day 0.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo 400 mg
- DIETARY_SUPPLEMENT Dihydroberberine（DHB）400 mg
Study Locations (1)
Illinois
- Merieux NutriSciences - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2026-03-15 |
| Phase | NA |
What NCT07210684 shows while recruiting
NCT07210684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (92% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo 400 mg is the first listed.
NCT07210684 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07210684 about?
NCT07210684 is a clinical study titled "Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes". The goal of this clinical trial is to learn if Dihydroberberine (DHB) supplementation affects adults with pre-diabetes. The main questions it aims to answer are: Does DHB supplementation increase the concentration of GLP-1 in the blood? Does DHB supplementation affect appetite, mood, and energy le...
What is the current status of trial NCT07210684?
This trial is currently recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2025-08-06. Estimated completion is 2026-03-15.
What conditions does trial NCT07210684 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT07210684?
The interventions under investigation include: Placebo 400 mg (DIETARY_SUPPLEMENT), Dihydroberberine（DHB）400 mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07210684?
This trial is sponsored by Nanjing Nutrabuilding Bio-tech Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210684 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07210684's enrollment target sits among peer trials
54 100th of 149 higher than 50 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Cleaner Air for Lower Cardiometabolic Risk
RECRUITING · NA
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI